MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.15

-0.3%

Nov 3 1:15 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	9/12/2008 5:24:59 PM
	Read Replies (1) of 2240

Update on Ipilimumab Trials [ from the Melanoma International Foundation website] The news from Bristol Myers Squibb today is mixed. High enrollments in compassionate use trials using ipilimumab depleted the product supply at a rate faster than anticipated. As a result of high enrollment, with 30 to 40 percent of patients continuing in maintenance, the demand has exceeded supply for new patients. Therefore, effective today, September 12, 2008, enrollment of new patients into the compassionate use program will need to be suspended. This will ensure patients who have already begun Ipilimumab treatment will continue to receive Ipilimumab as will those already registered in trials. According to the company "these actions shall be in place into 2009 until we have adequate product to meet demand or until Ipilimumab becomes commercially available." Stay tuned as we find out more. z2systems.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next